{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:54:00Z","timestamp":1760244840587,"version":"build-2065373602"},"reference-count":59,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T00:00:00Z","timestamp":1669766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Aberrant crypt foci (ACF) are one of the earliest putative preneoplastic and, in some cases, neoplastic lesions in human colons. Many studies have confirmed the reduction of ACFs and colorectal adenomas after treatment with acetylsalicylic acid (ASA) commonly referred to as ASA; however, the minimum effective dose of ASA and the duration of use has not been fully elucidated. The objective of our study was to assess the significance of low dose ASA (75-mg internally once daily) to study the chemopreventive effect of ASA in ACF and adenomas development in patients taking this drug for a minimum period of 10 years. Materials and\u00a0Methods: Colonoscopy, combined with rectal mucosa staining with 0.25% methylene blue, was performed on 131 patients. The number of rectal ACF in the colon was divided into three groups: ACF &lt; 5; ACF 5\u201310; and ACF &gt; 10. Patients were divided into two groups: the \u201cWith ASA\u201d group (the study group subjects taking ASA 75-mg daily for 10 years); and \u201cWithout ASA\u201d group (control group subjects not taking ASA chronically). The incidence of different types of rectal ACF and colorectal polyps in both groups of subjects was analysed and ascertained. Results: Normal ACF was found in 12.3% in the study group vs. 87.7% control group, hyperplastic 22.4% vs. 77.6%, dysplastic 25% vs. 75%, mixed 0% vs. 100%. Treatment with ASA affects the occurrence of colorectal adenomas. The amount of dysplastic ACFs was lower in the study group than in the control group. The increase in dysplastic ACFs decreases with age in both groups, with the increase greater in those not taking ASA. Conclusions: Patients who take persistent, chronic (&gt;10 years) low doses of ASA have a lower total number of all types of rectal ACFs and adenomas compared to the control group.<\/jats:p>","DOI":"10.3390\/medicina58121767","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T08:46:41Z","timestamp":1669798001000},"page":"1767","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Effect of Low Doses of Acetylsalicylic Acid on the Occurrence of Rectal Aberrant Crypt Foci"],"prefix":"10.3390","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4202-023X","authenticated-orcid":false,"given":"Marek","family":"Kowalczyk","sequence":"first","affiliation":[{"name":"Department of Psychology and Sociology of Health and Public Health, University of Warmia and Mazury, 10-719 Olsztyn, Poland"},{"name":"Clinic of Oncological and General Surgery, University Clinical Hospital in Olsztyn, 11-041 Olsztyn, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4799-9611","authenticated-orcid":false,"given":"Dawid","family":"Sigorski","sequence":"additional","affiliation":[{"name":"Department of Oncology, Collegium Medicum, University of Warmia and Mazury, 10-719 Olsztyn, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9734-2127","authenticated-orcid":false,"given":"\u0141ukasz","family":"Dy\u015bko","sequence":"additional","affiliation":[{"name":"Clinic of Oncological and General Surgery, University Clinical Hospital in Olsztyn, 11-041 Olsztyn, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0013-6448","authenticated-orcid":false,"given":"Ewa","family":"Zieli\u0144ski","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, 85-067 Bydgoszcz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana","family":"Zupanovich Lucka","sequence":"additional","affiliation":[{"name":"Department of Business, Fresno Pacific University, Fresno, CA 93702, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9131-2522","authenticated-orcid":false,"given":"\u0141ukasz","family":"Klepacki","sequence":"additional","affiliation":[{"name":"Department of Anatomy, University of Warmia and Mazury, 11-041 Olsztyn, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,30]]},"reference":[{"key":"ref_1","unstructured":"(2022, September 01). Cancer Stat Facts: Colorectal Cancer, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/colorect.html."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1056\/NEJM199901143400204","article-title":"Calcium Supplements for the Prevention of Colorectal Adenomas","volume":"340","author":"Baron","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1056\/NEJMoa061355","article-title":"Celecoxib for the Prevention of Sporadic Colorectal Adenomas","volume":"355","author":"Bertagnolli","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/S0016-5085(03)00887-4","article-title":"Daily soluble aspirin and prevention of colorectal adenoma recurrence: One-year results of the APACC trial","volume":"125","author":"Benamouzig","year":"2003","journal-title":"Gastroenterology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJM199810293391803","article-title":"Aberrant Crypt Foci of the Colon as Precursors of Adenoma and Cancer","volume":"339","author":"Takayama","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1111\/j.1572-0241.2005.40891.x","article-title":"Rectal Aberrant Crypt Foci Identified Using High-Magnification-Chromoscopic Colonoscopy: Biomarkers for Flat and Depressed Neoplasia","volume":"100","author":"Hurlstone","year":"2005","journal-title":"Am. J. Gastroenterol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1111\/j.1572-0241.2006.00578.x","article-title":"Assessment of Rectal Aberrant Crypt Foci by Standard Chromoscopy and its Predictive Value for Colonic Advanced Neoplasms","volume":"101","author":"Seike","year":"2006","journal-title":"Am. J. Gastroenterol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Kowalczyk, M., Or\u0142owski, M., Klepacki, \u0141., Zinkiewicz, K., Kurpiewski, W., Kaczerska, D., Pesta, W., Zieli\u0144ski, E., and Siermontowski, P. (2020). Rectal aberrant crypt foci (ACF) as a predictor of benign and malignant neoplastic lesions in the large intestine. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-6590-4"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1136\/gut.48.5.660","article-title":"Non-steroidal anti-inflammatory drugs with activity against either cyclooxygenase 1 or cyclooxygenase 2 inhibit colorectal cancer in a DMH rodent model by inducing apoptosis and inhibiting cell proliferation","volume":"48","author":"Brown","year":"2001","journal-title":"Gut"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1158\/1940-6207.CAPR-19-0167","article-title":"Efficacy of Difluoromethylornithine and Aspirin for Treatment of Adenomas and Aberrant Crypt Foci in Patients with Prior Advanced Colorectal Neoplasms","volume":"12","author":"Sinicrope","year":"2019","journal-title":"Cancer Prev. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1136\/gut.52.11.1598","article-title":"Suppressive effect of aspirin on aberrant crypt foci in patients with colorectal cancer","volume":"52","author":"Shpitz","year":"2003","journal-title":"Gut"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1096\/fj.00-0529fje","article-title":"Aspirin-induced activation of the NF-kappaB signaling pathway: A novel mechanism for aspirin-mediated apoptosis in colon cancer cells","volume":"15","author":"Stark","year":"2001","journal-title":"FASEB J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1038\/sj.onc.1210891","article-title":"The proapoptotic effects of sulindac, sulindac sulfone and indomethacin are mediated by nucleolar translocation of the RelA(p65) subunit of NF-\u03baB","volume":"27","author":"Loveridge","year":"2008","journal-title":"Oncogene"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s00018-008-7511-x","article-title":"NSAIDs and apoptosis","volume":"65","author":"Jana","year":"2008","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1093\/carcin\/bgm101","article-title":"Aspirin blocks proliferation in colon cells by inducing a G 1 arrest and apoptosis through activation of the checkpoint kinase ATM","volume":"28","author":"Luciani","year":"2007","journal-title":"Carcinogenesis"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.3390\/ph3072007","article-title":"NSAIDs and Cell Proliferation in Colorectal Cancer","volume":"3","author":"Ettarh","year":"2010","journal-title":"Pharmaceuticals"},{"key":"ref_17","first-page":"147","article-title":"What aspirin dosing should be used in everyday clinical practice? The multidisciplinary expert opinion","volume":"13","author":"Filipiak","year":"2016","journal-title":"Chor. Serca Naczy\u0144"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1161\/01.STR.0000231683.43347.ec","article-title":"Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers","volume":"37","author":"Cox","year":"2006","journal-title":"Stroke"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJM198411083111902","article-title":"Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase","volume":"311","author":"Pedersen","year":"1984","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0046-8177(91)90163-J","article-title":"Identification and quantification of aberrant crypt foci and microadenomas in the human colon","volume":"22","author":"Roncucci","year":"1991","journal-title":"Hum. Pathol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Percario, R., Panaccio, P., di Mola, F.F., Grottola, T., and Di Sebastiano, P. (2021). The Complex Network between Inflammation and Colorectal Cancer: A Systematic Review of the Literature. Cancers, 13.","DOI":"10.3390\/cancers13246237"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/gut.38.1.79","article-title":"Cyclooxygenase-1 and cyclooxygenase-2 gene expression in human colorectal adenocarcinomas and in azoxymethane induced colonic tumours in rats","volume":"38","author":"Lilja","year":"1996","journal-title":"Gut"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0092-8674(00)81988-1","article-title":"Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)","volume":"87","author":"Oshima","year":"1996","journal-title":"Cell"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1136\/gutjnl-2014-308260","article-title":"Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: A meta-analysis","volume":"64","author":"Li","year":"2015","journal-title":"Gut"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1001\/jama.2009.1112","article-title":"Aspirin use and survival after diagnosis of colorectal cancer","volume":"302","author":"Chan","year":"2009","journal-title":"JAMA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1084\/jem.190.4.445","article-title":"The Role of Cyclooxygenase Inhibition in the Antineoplastic Effects of Nonsteroidal Antiinflammatory Drugs (Nsaids)","volume":"190","author":"Shiff","year":"1999","journal-title":"J. Exp. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e22402","DOI":"10.1097\/MD.0000000000022402","article-title":"The efficacy and safety of sulindac for colorectal polyps","volume":"99","author":"Long","year":"2020","journal-title":"Medicine"},{"key":"ref_28","first-page":"3110","article-title":"Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis","volume":"55","author":"Piazza","year":"1995","journal-title":"Cancer Res."},{"key":"ref_29","first-page":"893","article-title":"The anti-proliferative effect of sulindac and sulindac sulfide on HT-29 colon cancer cells: Alterations in tumor suppressor and cell cycle-regulatory proteins","volume":"12","author":"Goldberg","year":"1996","journal-title":"Oncogene"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0304-3835(97)04740-X","article-title":"Sulindac sulfide inhibits the proliferation of colon cancer cells: Diminished expression of the proliferation markers PCNA and Ki-67","volume":"115","author":"Qiao","year":"1997","journal-title":"Cancer Lett."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1093\/eurheartj\/ehv505","article-title":"Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: Review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology","volume":"37","author":"Schmidt","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1158\/1078-0432.CCR-10-2395","article-title":"Randomized double-blind trial of sulindac and etodolac to eradicate aberrant crypt foci and to prevent sporadic colorectal polyps","volume":"17","author":"Takayama","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1001\/jama.294.1.47","article-title":"Low-Dose Aspirin in the Primary Prevention of Cancer","volume":"294","author":"Cook","year":"2005","journal-title":"JAMA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.gie.2007.08.048","article-title":"The natural history of aberrant crypt foci","volume":"67","author":"Schoen","year":"2008","journal-title":"Gastrointest. Endosc."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.canlet.2006.11.009","article-title":"Epidemiology of colonic aberrant crypt foci: Review and analysis of existing studies","volume":"252","author":"Stevens","year":"2007","journal-title":"Cancer Lett."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1056\/NEJMoa021735","article-title":"A Randomized Trial of Aspirin to Prevent Colorectal Adenomas","volume":"348","author":"Baron","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa021633","article-title":"A Randomized Trial of Aspirin to Prevent Colorectal Adenomas in Patients with Previous Colorectal Cancer","volume":"348","author":"Sandler","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"157","DOI":"10.7326\/0003-4819-140-3-200402030-00006","article-title":"A Prospective Study of Aspirin Use and the Risk for Colorectal Adenoma","volume":"140","author":"Chan","year":"2004","journal-title":"Ann. Intern. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/00001648-200007000-00003","article-title":"Reduced Incidence of Colorectal Adenoma among Long-Term Users of Nonsteroidal Antiinflammatory Drugs: A Pooled Analysis of Published Studies and a New Population-Based Study","volume":"11","year":"2000","journal-title":"Epidemiology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1023\/A:1024990617158","article-title":"Non-steroidal anti-inflammatory drug use is associated with reduction in recurrence of advanced and non-advanced colorectal adenomas (United States)","volume":"14","author":"Tangrea","year":"2003","journal-title":"Cancer Causes Control"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJM200006293422603","article-title":"The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis","volume":"342","author":"Steinbach","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1093\/jnci\/89.15.1152","article-title":"Suppression of Human Colorectal Mucosal Prostaglandins: Determining the Lowest Effective Aspirin Dose","volume":"89","author":"Ruffin","year":"1997","journal-title":"JNCI"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1093\/jnci\/djab009","article-title":"Timing of Aspirin Use in Colorectal Cancer Chemoprevention: A Prospective Cohort Study","volume":"113","author":"Zhang","year":"2021","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"39S","DOI":"10.1378\/chest.119.1_suppl.39S","article-title":"Platelet-active drugs: The relationships among dose, effectiveness, and side effects","volume":"119","author":"Patrono","year":"2001","journal-title":"Chest"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1073\/pnas.95.2.681","article-title":"Mechanisms underlying nonsteroidal antiinflammatory drug-mediated\u2009apoptosis","volume":"95","author":"Chan","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0092-8674(00)81433-6","article-title":"Cyclooxygenase Regulates Angiogenesis Induced by Colon Cancer Cells","volume":"93","author":"Tsujii","year":"1998","journal-title":"Cell"},{"key":"ref_47","first-page":"7","article-title":"The role of dietary components and different substance in the development of cancer","volume":"2","author":"Kardasz","year":"2008","journal-title":"Nowa Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/jnci\/djn484","article-title":"Nonsteroidal Anti-inflammatory Drug Use After 3 Years of Aspirin Use and Colorectal Adenoma Risk: Observational Follow-up of a Randomized Study","volume":"101","author":"Grau","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1093\/jnci\/85.15.1220","article-title":"Low-Dose Aspirin and Incidence of Colorectal Tumors in a Randomized Trial","volume":"85","author":"Gann","year":"1993","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"i6188","DOI":"10.1136\/bmj.i6188","article-title":"Chemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: Systematic review and network meta-analysis","volume":"355","author":"Dulai","year":"2016","journal-title":"BMJ"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1542-3565(04)00623-8","article-title":"Relationship of aging and tobacco use with the development of aberrant crypt foci in a predominantly African-American population","volume":"3","author":"Moxon","year":"2005","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1158\/1055-9965.EPI-04-0058","article-title":"Risk Factors for Colorectal Cancer in Relation to Number and Size of Aberrant Crypt Foci in Humans","volume":"14","author":"Rudolph","year":"2005","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Kowalczyk, M., Or\u0142owski, M., Siermontowski, P., Mucha, D., Zinkiewicz, K., Kurpiewski, W., Zieli\u0144ski, E., Kowalczyk, I., and Pedrycz, A. (2018). Occurrence of colorectal aberrant crypt foci depending on age and dietary patterns of patients. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4100-8"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Kowalczyk, M., Siermontowski, P., Mucha, D., Ambro\u017cy, T., Or\u0142owski, M., Zinkiewicz, K., Kurpiewski, W., Pa\u015bnik, K., Kowalczyk, I., and Pedrycz, A. (2016). Chromoendoscopy with a Standard-Resolution Colonoscope for Evaluation of Rectal Aberrant Crypt Foci. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0148286"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Kowalczyk, M., Klepacki, \u0141., Zieli\u0144ski, E., Kurpiewski, W., Zinkiewicz, K., Dy\u015bko, \u0141., and Pesta, W. (2021). The Effect of Smoking on the Number and Type of Rectal Aberrant Crypt Foci (ACF)\u2014First Identifiable Precursors of Colorectal Cancer (CRC). J. Clin. Med., 10.","DOI":"10.3390\/jcm10010055"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/carcin\/20.3.425","article-title":"Prevention by aspirin and its combination with \u03b1-difluoromethylornithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin E2 levels in rat colon","volume":"20","author":"Li","year":"1999","journal-title":"Carcinogenesis"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Higurashi, T., Arimoto, J., Ashikari, K., Takatsu, T., Misawa, N., Yoshihara, T., Matsuura, T., Fuyuki, A., Ohkubo, H., and Nakajima, A. (2020). The efficacy of aspirin and metformin combination therapy in patients with rectal aberrant crypt foci: A double-blinded randomized controlled trial. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-07564-z"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1158\/1940-6207.CAPR-10-0186","article-title":"Metformin Suppresses Colorectal Aberrant Crypt Foci in a Short-term Clinical Trial","volume":"3","author":"Hosono","year":"2010","journal-title":"Cancer Prev. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1470-2045(15)00565-3","article-title":"Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: A multicentre double-blind, placebo-controlled, randomised phase 3 trial","volume":"17","author":"Higurashi","year":"2016","journal-title":"Lancet Oncol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/58\/12\/1767\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:30:37Z","timestamp":1760146237000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/58\/12\/1767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,30]]},"references-count":59,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["medicina58121767"],"URL":"https:\/\/doi.org\/10.3390\/medicina58121767","relation":{},"ISSN":["1648-9144"],"issn-type":[{"type":"electronic","value":"1648-9144"}],"subject":[],"published":{"date-parts":[[2022,11,30]]}}}